/

CMND

Clearmind Medicine Inc.Closed

6.23−0.39 −5.82%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

6.42

Prev close

6.62

Day range

6.236.73

52-week range

5.253,840.00

Volume

10.95K0.17×

Mkt cap

3.16M

P/E ttm

—

Fwd P/E

—

EPS ttm

-434.34

Div yield

0.00%

Earnings

—

From 52w high

−99.84%

Price Chart

Yahoo Finance · delayed

CMNDOct 13, 2026O 6.50H 6.73L 6.23C 6.23−0.31 (−4.74%)Vol 11.00K

SMA 5010.17
SMA 20059.26

1Y change −99.80% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CMND Clearmind Medicine Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +6.68%
1 month: −19.47%
3 months: −59.65%
6 months: −91.44%
Year to date: −95.70%
1 year: −99.80%

Valuation & ownership

Market cap: 3.16M
Enterprise value: −11.51M
P/E (ttm): —
Forward P/E: —
PEG ratio: —
Price / book: 0.13
Price / sales (ttm): —
EV / EBITDA: 1.30
EPS (ttm): -434.34
EPS (forward): —
Beta (5y monthly): 0.46
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 507.40K
Float: 419.17K
Short % of float: 0.37%
Short ratio (days): 0.01
Held by insiders: 0.03%
Held by institutions: 1.21%
Avg volume (3m): 64.00K
50-day average: 10.30
200-day average: 60.15
52-week change: −99.80%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 35.0
vs 50-day SMA: −38.72%
vs 200-day SMA: −89.49%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 12.07%
Realised vol (20d, ann.): 88.1%
From 52-week high: −99.84%
From 52-week low: +18.67%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About Clearmind Medicine Inc.

Yahoo Finance profile

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Sector: Healthcare
Industry: Biotechnology
Headquarters: Vancouver, BC, Canada
Website: clearmindmedicine.com
Officers: Dr. Adi Zuloff-Shani Ph.D. Chief Executive Officer
Mr. Alan Mark Rootenberg B.Com., B.Comm, C.A., C.P.A. Chief Financial Officer
Prof. Mark Haden M.S.W. Vice President of Business Development

SEAS

Seasonality · CMND

2022–2026 · monthly returns

Strongest month Jun +8.04%Weakest month Mar −34.76%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	19.9	-47.9	-8.0	-31.5	-49.7	-38.5	-23.2	14.8	-58.5	-3.3			−95.7%
2025	0.0	-12.3	-14.5	-2.4	-4.8	-6.4	11.1	5.5	-2.8	-22.3	-80.5	-70.8	−96.7%
2024	-49.1	7.7	-25.3	3.3	-4.9	48.7	-1.2	-21.1	-6.9	13.9	-6.5	6.2	−50.9%
2023	13.0	-9.2	-64.5	-51.7	4.5	-18.1	-7.4	-11.1	-59.1	-23.8	-4.4	-19.7	−97.0%
2022												-18.3	−18.3%

INSD

Insider Activity · CMND

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

2.16M shares

Sells, 6 months

252.6K shares

Net shares

+1.91M

Net change in insider shares

−100.00%

Date	Insider	Transaction	Shares	Value
Jun 15, 2026	Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security	Sale at price 3.31 per share.	22.1K	$73.19K
Jun 14, 2026	Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security	Sale at price 3.32 per share.	3.2K	$10.57K
Jun 11, 2026	Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security	Sale at price 3.36 per share.	2.1K	$7.06K
Jun 10, 2026	Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security	Sale at price 3.34 per share.	225.2K	$752.14K
Jun 9, 2026	Hrt Financial L.PBeneficial Owner of more than 10% of a Class of Security	Purchase at price 3.20 per share.	2.16M	$6.91M

CMND

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CMND

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Clearmind Medicine Inc.

Seasonality · CMND

Insider Activity · CMND

Congress Trades · CMND

Investors Holding CMND

Investors Holding CMND

Congress Trades · CMND

Insider Activity · CMND

Seasonality · CMND

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Clearmind Medicine Inc.

Earnings & Dividends

News